Dr. Vij on Tumor Bank for Multiple Myeloma at Siteman Cancer Center

Video

In Partnership With:

Ravi Vij, MD, associate professor, medicine, Division of Oncology, Section of Bone Marrow Transplant, Siteman Cancer Center, discusses the institution's tumor banking initiative for next-generation sequencing in multiple myeloma.

Ravi Vij, MD, associate professor, medicine, Division of Oncology, Section of Bone Marrow Transplant, Siteman Cancer Center, discusses the institution's tumor banking initiative for next-generation sequencing in multiple myeloma.

Initially, the tumor banking initiative at Siteman Cancer Center was set up to research acute myeloid leukemia and myelodysplastic syndrome, Vij says. The tumor tissues were eventually used for next-generation sequencing, which has helped with the genomics of these diseases to help develop targeted therapies.

The tumor bank is being pulled from again, Vij explains, to research next-generation sequencing in multiple myeloma. Coupled with new technologies, it will help to better define the mutational spectrum of patients with multiple myeloma. These tissues are also to be used in collaboration with other institutions and companies to help improve outcomes of these patients.

Additional tumor bank initiatives are taking place at other institutions for other malignancies, Vij says.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD